DeZwarteRidder schreef op 15 april 2019 14:44:
allemaal mislukkingen:
--------------------------------------------------------------------------
Archive: 2004
We are committed to open and transparent communications with the investment community. Probiodrug’s announcements will be made mainly in English.
Morphochem and Probiodrug collaborate in research and development of novel innovative dipeptidyl peptidase IV (DP IV) inhibitors for the treatment of Anxiety and Depression
Published: 18.11.04
Halle (Saale), Germany // Probiodrug AG Morphochem AG and Probiodrug AG today announced that they have entered into a research and collaboration for the development of novel small molecule therapeutics, initially focused on the inhibition of the serine protease dipeptidyl peptidase IV (DP IV) for the treatment of Anxiety and Depression. Under the multi-year program, […]
Tagged with: press release , probiodrug
Read more
=========================================================================
Closing of Probiodrug-Prosidion Transaction and Changes in Management & Board
Published: 16.08.04
Halle (Saale), Germany // Probiodrug AG Probiodrug announced today that all closing conditions to finalize the Probiodrug-Prosidion transaction have been fulfilled. In connection with the transaction, Dr. Konrad Glund resigned from his position as Co-CEO of Probiodrug and takes over the position “Vice President of Corporate Development” at Prosidion. As part of this change Dr. […]
Tagged with: press release , probiodrug
Read more
==========================================================================
Probiodrug awarded a € 1.9mio BioChancePlus grant to fund a drug-discovery program for the treatment of neurodegenerative disorders
Published: 06.07.04
Halle (Saale), Germany // Probiodrug AG, a drug development company, has been awarded a €1.9mio grant from the German Federal Department of Education and Research under the BioChancePlus program. The grant will fund a drug-discovery program including the identification and characterization of small-molecule lead compounds for the inhibition of new target proteins potentially involved in […]
Tagged with: press release , probiodrug
Read more
=========================================================================
Osi Pharmaceuticals’ Subsidary Prosidion Acquires Dipeptidyl Peptidase IV Platform From Probiodrug / Includes Phase II Development Candidate P93/01
Published: 18.06.04
Melville, New York, USA // Oxford, United Kingdom // Halle (Saale), Germany OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), Prosidion Limited, a subsidiary of OSI focused on the discovery and development of diabetes and obesity therapeutics, and Probiodrug AG announced today that Prosidion has agreed to purchase a platform of Dipeptidyl Peptidase IV (DP-IV) technology from Probiodrug […]
Tagged with: press release , probiodrug
Read more
==========================================================================
Update on Probiodrug’s Patents
Published: 12.05.04
Status of opposition OF EP 0896538 During May 11-12, 2004, oral hearings were held at the European Patent Office in Munich concerning the oppositions filed against EP 0896538, which belongs to the patent family of WO 97/40833. The Board of Examiners, after hearing oral testimony from opponents and patentees over 1.5 days, ruled that the […]
Tagged with: press release , probiodrug
Read more
=======================================================================